Systemic Lupus Erythematosus (Immunology) - Drugs in Development, 2021

September 2021 | 1013 pages | ID: S24D144BEDF4EN
Global Markets Direct

Abstracts

Systemic Lupus Erythematosus (Immunology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Drugs In Development, 2021, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 48, 34, 4, 81, 27 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 1, 13 and 2 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
• The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Systemic Lupus Erythematosus - Overview
Systemic Lupus Erythematosus - Therapeutics Development
Systemic Lupus Erythematosus - Therapeutics Assessment
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
Systemic Lupus Erythematosus - Drug Profiles
Systemic Lupus Erythematosus - Dormant Projects
Systemic Lupus Erythematosus - Discontinued Products
Systemic Lupus Erythematosus - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Systemic Lupus Erythematosus, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Abcentra LLC, 2021
Systemic Lupus Erythematosus - Pipeline by Accro BioScience (Suzhou) Co Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Akeso Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Alexion Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Alphamab Oncology, 2021
Systemic Lupus Erythematosus - Pipeline by Alpine Immune Sciences Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Aluda Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Amgen Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Ampio Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Annexon Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Apellis Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Apimeds Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Aprilbio Co Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by APT Therapeutics Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Aria Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, 2021
Systemic Lupus Erythematosus - Pipeline by Astellas Pharma Inc, 2021
Systemic Lupus Erythematosus - Pipeline by AstraZeneca Plc, 2021
Systemic Lupus Erythematosus - Pipeline by Athos Therapeutics Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Avotres Inc, 2021
Systemic Lupus Erythematosus - Pipeline by BeiGene Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Beijing Mabworks Biotech Co Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by BellBrook Labs LLC, 2021
Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, 2021
Systemic Lupus Erythematosus - Pipeline by BioAegis Therapeutics Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Biocon Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Biogen Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Biotest AG, 2021
Systemic Lupus Erythematosus - Pipeline by BioTherapeutics Inc, 2021
Systemic Lupus Erythematosus - Pipeline by BioTheryX Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim International GmbH, 2021
Systemic Lupus Erythematosus - Pipeline by Boston Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Brickell Biotech Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, 2021
Systemic Lupus Erythematosus - Pipeline by Capricor Therapeutics Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Carna Biosciences Inc, 2021
Systemic Lupus Erythematosus - Pipeline by CellionBioMed Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Cells for Cells SA, 2021
Systemic Lupus Erythematosus - Pipeline by Centessa Pharmaceuticals Plc, 2021
Systemic Lupus Erythematosus - Pipeline by Centivax Inc, 2021
Systemic Lupus Erythematosus - Pipeline by ChemoCentryx Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Chinook Therapeutics Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021
Systemic Lupus Erythematosus - Pipeline by Citryll BV, 2021
Systemic Lupus Erythematosus - Pipeline by Corbus Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Corestem Inc, 2021
Systemic Lupus Erythematosus - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Daiichi Sankyo Co Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Eledon Pharmaceuticals Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, 2021
Systemic Lupus Erythematosus - Pipeline by Epsilon-3 Bio Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Ergon Pharmaceuticals LLC, 2021
Systemic Lupus Erythematosus - Pipeline by Exinda Therapeutics LLC, 2021
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Galapagos NV, 2021
Systemic Lupus Erythematosus - Pipeline by Genentech USA Inc, 2021
Systemic Lupus Erythematosus - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by Genesen Co Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Genosco Inc, 2021
Systemic Lupus Erythematosus - Pipeline by Genovax Srl, 2021
Systemic Lupus Erythematosus - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2021
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, 2021
Systemic Lupus Erythematosus - Pipeline by Good T Cells Inc, 2021
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, 2021
Systemic Lupus Erythematosus - Dormant Projects, 2021
Systemic Lupus Erythematosus - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Systemic Lupus Erythematosus, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021